Widening spectrum of neuroleptic malignant syndrome: Case series.
Publication/Presentation Date
1-1-2022
Abstract
Neuroleptic malignant syndrome (NMS) is a rare and rapidly progressive syndrome with mortality rate of 5.6%. The spectrum of onset, progression and outcome is heterogeneous and is associated with number of risk factors. In our case series, we entail the triggers, hospital course and outcome of five interesting in-patient cases that were admitted to our service in a tertiary care hospital in Northern India. This case series is to highlight the first ever reported case of NMS triggered by levosulpiride administration, along with one of the few first cases of NMS after programming of DBS, hypothyroid disorders, levodopa readjustment and selective basal ganglia and cerebellar injury following the hyperthermic syndrome. This is also to bring to attention of clinicians worldwide the atypical risk factors of NMS, and stress the importance of staying vigilant for the same by frequent follow-ups and high degree of clinical suspicion. We also aim to generate epidemiological data about these atypical triggers.
Volume
38
Issue
2
First Page
309
Last Page
314
ISSN
0970-9185
Published In/Presented At
Paul, G., Singhal, S., Paul, B. S., Singh, G., & Goyal, S. (2022). Widening spectrum of neuroleptic malignant syndrome: Case series. Journal of anaesthesiology, clinical pharmacology, 38(2), 309–314. https://doi.org/10.4103/joacp.JOACP_8_21
Disciplines
Medicine and Health Sciences
PubMedID
36171930
Department(s)
Fellows and Residents
Document Type
Article